Detalles de la búsqueda
1.
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Lancet Oncol
; 23(6): 781-792, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35576957
2.
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.
J Thorac Oncol
; 16(2): 205-215, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33096270
3.
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
JAMA Oncol
; 4(3): 351-357, 2018 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29327044
4.
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
Clin Lung Cancer
; 18(1): 68-76.e2, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28341109
Resultados
1 -
4
de 4
1
Próxima >
>>